CLAIMS:

1. Form II polymorph of ferric maltol characterized by a powder X-ray diffraction pattern comprising a characteristic crystalline peak expressed in degrees 2-theta at 8.3 ±0.25 degrees.

2. The polymorph of Claim 1, characterised by a powder X-ray diffraction pattern comprising one or more further peaks expressed in degrees 2-theta selected from about 11.8,12.5, 13.4, 14.5, 15.5, 15.6, 16.2, 16.7, 18.7, 19.2, 19.9, 20.6, 21.1, 22.8, 23.7, 24.6, 25.1, 25.7, 27.1, or 29.1 ±0.2, or ±0.1 such as about ±0.05 degrees.

3. The polymorph of Claim 1 or Claim 2, characterised by a powder X-ray diffraction pattern comprising two or more, three or more, or four or more further peaks expressed in degrees 2-theta selected from about 11.8, 12.5, 13.4, 14.5, 15.5, 15.6, 16.2, 16.7, 18.7, 19.2, 19.9, 20.6, 21.1, 22.8, 23.7, 24.6, 25.1, 25.7, 27.1, or 29.1 ±0.2, or ±0.1 such as about ±0.05 degrees.

4. The polymorph of any one of Claims 1 to 3, wherein the polymorph is characterised by a powder X-ray diffraction pattern comprising peaks expressed in degrees 2-theta at each of about 8.3, 11.8, 13.4, 14.5, and 15.6, and, optionally, one or more, two or more, three or more or each of 15.5, 16.7, 21.1, 22.8, and 24.6 degrees ±0.25, or ±0.2, or ±0.1 such as about ±0.05 degrees.

5. A process for the preparation of a form as claimed in any one of Claims 1 to 4, which comprises combining ferric citrate with maltol anions in solution to form ferric maltol polymorph Form II, wherein the process comprises the use of a ferric maltol seed crystal comprising Form I and/or Form II polymorph.

6. Form I polymorph of ferric maltol characterized by a powder X-ray diffraction pattern comprising characteristic crystalline peaks expressed in degrees 2-theta at 15.6 and 22.5 ± 0.25 degrees, optionally wherein the polymorph comprises at least about 92 wt.% ferric maltol based on the weight of the polymorph.

7. The polymorph of Claim 6, characterised by a powder X-ray diffraction pattern comprising one or more further peaks expressed in degrees 2-theta selected from about

11.4, 12.8, 13.7, 16.9, 18.5, 19.6, 20.0, 20.7, 23.0, 23.8, 25.2 or 25.8 ±0.25 or ±0.2, or ±0.1 such as about ±0.05 degrees and, optionally, wherein the diffraction pattern does not comprise peaks at any one of about 8.3 and about 11.7 degrees.

8. The polymorph of Claim 6 or Claim 7, characterised by a powder X-ray diffraction pattern comprising two or more, three or more, or four or more further peaks expressed in degrees 2-theta selected from about 11.4, 12.8, 13.7, 16.9, 18.5, 19.6, 20.0, 20.7, 23.0, 23.8, 25.2 or 25.8 degrees.

9. The polymorph of any one of Claims 6 to 8 wherein the polymorph comprises characteristic crystalline peaks with 2-Theta values (in degrees) at each of 11.4, 15.6, 16.9, 22.5, and 23.8, and, optionally, one or more, two or more, three or more or each of 13.7, 19.6, 20.7, 22.5, 25.2 and 25.8 ±0.2, or ±0.1 such as about ±0.05 degrees.

10. A process for the preparation of a form as claimed in any one of Claims 6 to 9, which comprises combining ferric citrate with maltol anions to form a mixture comprising ferric maltol polymorph Form I and wherein the process comprises the use of a ferric maltol seed crystal comprising Form I.

11. Form III polymorph of ferric maltol characterized by a powder X-ray diffraction pattern comprising a peak expressed in degrees 2-theta at 7.4 ±0.25 degrees.

12. The polymorph of Claim 11, characterised by a powder X-ray diffraction pattern comprising one or more, two or more, three or more, four or more or five or more further peaks expressed in degrees 2-theta selected from about 9.3, 10.5, 11.6, 13.6, 14.0, 15.1, 17.0, 17.7, 18.2, 18.7, 20.5, 21.2, 22.1, 22.5, 23.6, 24.9, 27.4 and 30.6 ±0.2, or ±0.1 such as about ±0.05 degrees.

13. The polymorph of Claim 11 or Claim 12 wherein the polymorph is characterised by a powder X-ray diffraction pattern comprising peaks expressed in degrees 2-theta at each of about 7.4, 9.3, 22.1, 22.5 and 23.6 ±0.2, or ±0.1 such as about ±0.05 degrees and, optionally, one or more, two or more, three or more, or each of, 11.6, 13.6, 14.0, 15.1, 17.0, 18.2, 24.9, or 27.4 ±0.2, or ±0.1 such as about ±0.05 degrees.

14. Form IV polymorph of ferric maltol characterized by a powder X-ray diffraction pattern comprising peaks expressed in degrees 2-theta at 9.5 and 14.5 ± 0.2 degrees.

15. The polymorph of Claim 14, characterised by a powder X-ray diffraction pattern comprising one or more further peaks expressed in degrees 2-theta selected from about 11.4, 12.8, 13.7, 15.5, 18.5, 19.9, 23.1, 25.0 and 25.8 ±0.2, or ±0.1 such as about ±0.05 degrees.

16. The polymorph of Claim 14 or Claim 15, wherein the polymorph is characterized by a powder X-ray diffraction pattern comprising peaks expressed in degrees 2-theta at each 9.5, 11.4, 12.8, 14.5 and 15.5, and, optionally, one or more, two or more, three or more or each of 13.7, 18.5, 19.9, 23.1, 25.0 and 25.8 degrees ±0.2, or ±0.1 such as about ±0.05 degrees.

17. A polymorph obtainable by a process according to Claim 5 or Claim 10.

18. A polymorph as defined in any one of Claims 1 to 4, 6 to 9 or 11 to 16, for use as a pharmaceutical.

19. A composition comprising a mixture of Form I and Form II polymorphs.

20. A pharmaceutical composition comprising a polymorph as defined in any one of Claims 1 to 4, 6 to 9, or 11 to 16, or a mixture thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.

21. A polymorph as defined in any one of Claims 1 to 4, 6 to 9, or 11 to 16 for use in the prevention or treatment of iron deficiency with or without anaemia in a subject, such as iron deficiency anaemia.

22. The use of a polymorph as defined in any one of Claims 1 to 4, 6 to 9, or 11 to 16 for the manufacture of a medicament for the prevention or treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia.